Drug Trial Radar · NCT05322473
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
234
Actual
Start
Apr 25, 2022
Primary completion
May 9, 2023
Study completion Aug 30, 2023
Sponsor
- Lead sponsor
- MoonLake Immunotherapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Apr 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
Conditions
- Hidradenitis Suppurativa
Interventions
Sonelokimab (M1095)Drug
randomized treatment; parallel-group
AdalimumabDrug
randomized treatment; parallel-group
PlaceboOther
randomized treatment; parallel-group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 12Time frame: At Week 12
Locations
57 sites in 7 countries. Site status is shown where the registry gives one.
Clinical Site
Fountain Valley, California
Clinical Site
Los Angeles, California
Clinical Site
Miami, Florida
Clinical Site
Ormond Beach, Florida
Clinical Site
St. Petersburg, Florida
Clinical Site
Tampa, Florida
Clinical Site
Indianapolis, Indiana
Clinical Site
Beverly, Massachusetts
Clinical Site
Boston, Massachusetts
Clinical Site
Omaha, Nebraska
Clinical Site
New York, New York
Clinical Site
Philadelphia, Pennsylvania
Clinical Site
Charleston, South Carolina
Clinical Site
Nashville, Tennessee
Clinical Site
Bellaire, Texas
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Stara Zagora, Bulgaria
Clinical Site
Calgary, Alberta, Canada
Clinical Site
Winnipeg, Manitoba, Canada
Clinical Site
Fredericton, New Brunswick, Canada
Clinical Site
St. John's, Newfoundland and Labrador, Canada
Clinical Site
Hamilton, Ontario, Canada
Clinical Site
London, Ontario, Canada
Clinical Site
Markham, Ontario, Canada
Clinical Site
Newmarket, Ontario, Canada
Clinical Site
Peterborough, Ontario, Canada
Clinical Site
Saskatoon, Saskatchewan, Canada
Clinical Site
Bad Bentheim, Germany
Clinical Site
Berlin, Germany
Clinical Site
Berlin, Germany
Clinical Site
Berlin, Germany
Clinical Site
Bochum, Germany
Clinical Site
Darmstadt, Germany
Clinical Site
Dresden, Germany
Clinical Site
Frankfurt, Germany
Clinical Site
Hamburg, Germany
Clinical Site
Kiel, Germany
Clinical Site
Lübeck, Germany
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.